Skip to main content
SpringerLink
Log in
Book cover

Principles of Pulmonary Protection in Heart Surgery pp 195–211Cite as

Pulmonary Arterial Hypertension

  • Chapter
  • First Online:

  • 1056 Accesses

Abstract

Pulmonary hypertension is a significant determinant of morbidity and mortality in patients undergoing cardiac surgery. The successful management of these patients requires an individualized and systematic approach. The analysis of preoperative risk factors, perioperative management of hemodynamics, and the prevention and early recognition of postoperative complications is imperative to successfully oversee the care of pulmonary hypertension patients undergoing cardiac surgery.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Zamanian R, Haddad F, Doyle RL, Weinacker A. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35(9):9037–9050.

    Google Scholar 

  2. Smetana G. Preoperative pulmonary evaluation. N Engl J Med. 1999;340:937-944.

    Article  PubMed  CAS  Google Scholar 

  3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.

    Article  PubMed  CAS  Google Scholar 

  4. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:78-92.

    Article  Google Scholar 

  5. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-492.

    PubMed  CAS  Google Scholar 

  6. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest. 2007;131(1):217-222.

    Article  PubMed  Google Scholar 

  7. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223.

    PubMed  CAS  Google Scholar 

  8. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest. 2004;126:145-305.

    Article  Google Scholar 

  9. Davies RJ, Morrell NW. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest. 2008;134(6):1271-1277.

    Article  PubMed  CAS  Google Scholar 

  10. Bates B, Bickley LS, Hoekelman RA. A guide to physical examination and history taking. 6th ed. Philadelphia: Lippincott; 1995.

    Google Scholar 

  11. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004;43(5):764-770.

    Article  PubMed  CAS  Google Scholar 

  12. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865-870.

    Article  PubMed  CAS  Google Scholar 

  13. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest. 2002;121:513-518.

    Article  PubMed  Google Scholar 

  14. Henkens IR, Mouchaers KT, Vliegen HW, et al. Early changes in rat hearts with developing pulmonary arterial hypertension can be detected with three-dimensional electrocardiography. Am J Physiol Heart Circ Physiol. 2007;293:H1300-H1307.

    Article  PubMed  CAS  Google Scholar 

  15. Viellard-Baron A, Prin S, Chergui K, et al. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medial intensive care unit. Am J Respir Crit Care Med. 2002;166:1310-1319.

    Article  Google Scholar 

  16. Forfia P, Fisher MR, Mathai SC, et al. Tricuspid annula displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034-1041.

    Article  PubMed  Google Scholar 

  17. Maslow AD, Regan MM, Panzica P, et al. Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. Anesth Analg. 2002;95:1507-1518.

    Article  PubMed  Google Scholar 

  18. Reichert CL, Visser CA, van den Brink RB, et al. Prognostic value of biventricular function in hypertensive patients after cardiac surgery as assessed by transesophageal echocardiography. J Cardiothorac Vasc Anesth. 1992;6:429-432.

    Article  PubMed  CAS  Google Scholar 

  19. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214-1219.

    Article  PubMed  Google Scholar 

  20. Yeo T, Dujardin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol. 1998;81:1157-1161.

    Article  PubMed  CAS  Google Scholar 

  21. Hüttemann E. Transesophageal echocardiography in the intensive care unit. Minerva Anestesiol. 2006;72:891-913.

    PubMed  Google Scholar 

  22. Berger M, Haimowitz A, Van Tosh A. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;2:359-365.

    Article  Google Scholar 

  23. Currie PJ, Seward JB, Chan K-L. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985;6:750-756.

    Article  PubMed  CAS  Google Scholar 

  24. Smetana GW. Preoperative pulmonary assessment of the older adult. Clin Geriatr Med. 2003;19:35-55.

    Article  PubMed  Google Scholar 

  25. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106:319-324.

    Article  PubMed  Google Scholar 

  26. Barst R, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40-47.

    Article  Google Scholar 

  27. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.

    PubMed  Google Scholar 

  28. Rodriguez R, Pearl R. Pulmonary hypertension and major surgery. Anesth Analg. 1998;87:812-815.

    PubMed  CAS  Google Scholar 

  29. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest. 1998;114:780-786.

    Article  PubMed  CAS  Google Scholar 

  30. Adatia I, Perry S, Landzberg M, et al. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol. 1995;25:1656-1664.

    Article  PubMed  CAS  Google Scholar 

  31. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389.

    PubMed  CAS  Google Scholar 

  32. Badesch DB, Abman SH, Simonneau G. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-1928.

    Article  PubMed  Google Scholar 

  33. Mahajan A, Shabanie A, Varshney SM, et al. Inhaled nitric oxide in the preoperative evaluation of pulmonary hypertension in heart transplant candidates. J Cardiothorac Vasc Anesth. 2007;1:51-56.

    Article  CAS  Google Scholar 

  34. Pearl R. Perioperative management of pulmonary hypertension: covering all aspects from risk assessment to postoperative considerations. Adv Pulm Hypertens Winter 2005:1–19

    Google Scholar 

  35. Solina AR, Ginserg SH, Papp D, et al. Response to nitric oxide during cardiac surgery. J Invest Surg. 2002;15:5-14.

    Article  PubMed  Google Scholar 

  36. Mauck KF, Manjarrez EC, Cohn SL. Perioperative cardiac evaluation: assessment, risk reduction, and complication management. Clin Geriatr Med 2008;24(4):595–605, vii.

    Google Scholar 

  37. Bapoje SR, Whitaker JF, Schulz T, et al. Preoperative evaluation of the patient with pulmonary disease. Chest. 2007;132:1637-1645.

    Article  PubMed  Google Scholar 

  38. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension. Chest. 2004;126:35-62.

    Article  Google Scholar 

  39. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: summary of recommendations from the chapter on medical therapies. Chest. 2002;131:1917-1928.

    Article  Google Scholar 

  40. Johnson SR, Metha S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28:999-1004.

    Article  PubMed  CAS  Google Scholar 

  41. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.

    Article  PubMed  CAS  Google Scholar 

  42. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112:714-721.

    Article  PubMed  CAS  Google Scholar 

  43. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114:787-792.

    Article  PubMed  CAS  Google Scholar 

  44. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.

    Article  PubMed  CAS  Google Scholar 

  45. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.

    Article  PubMed  CAS  Google Scholar 

  46. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-535.

    Article  PubMed  CAS  Google Scholar 

  47. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001;358:1119-1123.

    Article  PubMed  CAS  Google Scholar 

  48. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.

    Article  PubMed  CAS  Google Scholar 

  49. Galie N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind randomised controlled trial. Lancet. 2008;371:2093-2100.

    Article  PubMed  CAS  Google Scholar 

  50. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-2056.

    Article  PubMed  CAS  Google Scholar 

  51. Galie N, Olshewski H, Oudiz RJ. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117: 3010-3019.

    Article  PubMed  CAS  Google Scholar 

  52. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-447.

    Article  PubMed  Google Scholar 

  53. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.

    Article  PubMed  CAS  Google Scholar 

  54. Lepore JJ, Maroo A, Pereira NL, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677-680.

    Article  PubMed  CAS  Google Scholar 

  55. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.

    Article  PubMed  CAS  Google Scholar 

  56. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalfil and bosentan in healthy male subjects. J Clin Pharmacol. 2008;48:610-618.

    Article  PubMed  CAS  Google Scholar 

  57. Barst RJ, Brundage BH, Ghofrani A, et al. Tadalafil improves exercise capacity, health related quality of life and delays time to clinical worsening in patients with symptomatic pulmonary arterial hypertension (PAH). CHEST 2008: American College of Chest Physicians 74th Annual Scientific Assembly: Abstract AS2244. Presented 28 Oct 2008

    Google Scholar 

  58. Strauss WL, Edelman JD. Prostanoid therapy for pulmonary arterial hypertension. Clin Chest Med. 2007;28:127-142.

    Article  PubMed  Google Scholar 

  59. Barst RJ, Rubin LJ, Long WA, et al.; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-335.

    Article  Google Scholar 

  60. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. Chest. 1998;338:273-277.

    CAS  Google Scholar 

  61. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation. 2002;106:1477-1482.

    Article  PubMed  CAS  Google Scholar 

  62. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299.

    Article  PubMed  CAS  Google Scholar 

  63. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003;24:356-365.

    Article  PubMed  CAS  Google Scholar 

  64. Rex S, Schaelte G, Metzelder S, et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective randomized-controlled trial. Acta Anaesthesiol Scand. 2008;52:65-72.

    Article  PubMed  CAS  Google Scholar 

  65. Olshewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.

    Article  Google Scholar 

  66. Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;33(6):1354-1360.

    Article  PubMed  CAS  Google Scholar 

  67. Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest. 2006;130:841-846.

    Article  PubMed  Google Scholar 

  68. Lievre M, Morand S, Besse B, et al.; Beraprost et Claudication Intermittente (BERCI) Research Group. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Circulation. 2000;102:426-431.

    Article  Google Scholar 

  69. Vayssairat M. Preventive effect of oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol. 1999;26:2173-2178.

    PubMed  CAS  Google Scholar 

  70. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188-1192.

    Article  PubMed  CAS  Google Scholar 

  71. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119-2125.

    Article  PubMed  CAS  Google Scholar 

  72. O’Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med. 2007;28:169-185.

    Article  PubMed  Google Scholar 

  73. Ferguson MK. Preoperative assessment of pulmonary risk. Chest. 1999;115:58S-63S.

    Article  PubMed  CAS  Google Scholar 

  74. McGlothlin D, De Marco T. Preoperative risk assessment of pulmonary arterial hypertension patients undergoing general surgery. Adv Pulm Hypertens Summer 2007:67–72

    Google Scholar 

  75. Olsson JK, Zamanian RT, Feinstein JA, Doyle RL. Surgical and interventional therapies for pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005;26:417-428.

    Article  PubMed  Google Scholar 

  76. Sager JS, Ahya VN. Surgical therapies for pulmonary arterial hypertension. Clin Chest Med. 2007;28:187-202.

    Article  PubMed  Google Scholar 

  77. Rothman A, Sklansky MS, Lucas VW, Kashani IA. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol. 1999;84:682-686.

    Article  PubMed  CAS  Google Scholar 

  78. Law MA, Grifka RG, Mullins CE, Nihill MR. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J. 2007;153:779-784.

    Article  PubMed  Google Scholar 

  79. Sandova J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med. 2001;22(3):547-560.

    Article  Google Scholar 

  80. Auger WR, Kim NH, Kerr KM. Chronic thromboembolic pulmonary hypertension. Clin Chest Med. 2007;28:255-269.

    Article  PubMed  Google Scholar 

  81. Dartevelle P, Facel E, Mussot S, et al. Surgical treatment of pulmonary arterial hypertension. Rev Prat. 2008;58(18):2031-2035.

    PubMed  Google Scholar 

  82. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical modalities of treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:73S-80S.

    Article  PubMed  Google Scholar 

  83. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part 2: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117:1717-1731.

    Article  PubMed  Google Scholar 

  84. Greyson C. Pathophysiology of right ventricular failure. Crit Care Med. 2008;36:57-65.

    Article  Google Scholar 

  85. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2006;34:2814-2819.

    Article  PubMed  CAS  Google Scholar 

  86. Michaels AD, Chatterjee K, De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail. 2005;11:425-431.

    Article  PubMed  CAS  Google Scholar 

  87. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007;153:127-132.

    Article  PubMed  Google Scholar 

  88. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005;20: 171-176.

    Article  PubMed  Google Scholar 

  89. Hohn L, Schweizer A, Morel D, et al. Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology. 1999;91:1943-1945.

    Article  PubMed  CAS  Google Scholar 

  90. Via G, Braschi A. Pathophysiology of severe pulmonary hypertension in the critically ill patient. Minerva Anestesiol. 2004;70:233-237.

    PubMed  CAS  Google Scholar 

  91. Subramniam K, Yared JP. Management of pulmonary hypertension in the operating room. Semin Cardiothorac Vasc Anesth. 2007;2:119-136.

    Article  Google Scholar 

  92. Rich GF, Roos CM, Anderson SM, et al. Direct effects of intravenous anesthetics on pulmonary vascular resistance in the isolated rat lung. Anesth Analg. 1994;78:961-966.

    Article  PubMed  CAS  Google Scholar 

  93. Wiedemann K, Diestelhorst C. The effect of sedation on pulmonary function. Anaesthesist. 1995;44:588-593.

    Google Scholar 

  94. Malan TP, DiNardo JA, Isner RJ, et al. Cardiovascular effects of sevoflurane compared with those of isoflurane in volunteers. Anesthesiology. 1995;83:918-928.

    Article  PubMed  CAS  Google Scholar 

  95. Bennett SR, Griffin SC. Sevoflurane versus isoflurane in patients undergoing valvular cardiac surgery. J Cardiothorac Vasc Anesth. 2001;15:175-178.

    Article  PubMed  CAS  Google Scholar 

  96. Riabova OS, Vyzhigina MA, Zhukova SG, et al. Sevoflurane and isoflurane during thoracic operations under artificial one-lung ventilation in patients at a high surgical and anesthesiological risk. Anesteziol Reanimatol. 2007;2:15-21.

    PubMed  Google Scholar 

  97. Jenkins IR, Dolman J, O’Connor JP, Ansley DM. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: a prospective, randomized double-blinded trial. Anaesth Intensive Care. 1997;25:245-249.

    PubMed  CAS  Google Scholar 

  98. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia. 2002;57:9-14.

    Article  PubMed  CAS  Google Scholar 

  99. Braun EB, Palin CA, Hoque CW. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg. 2004;99:36-37.

    Article  PubMed  CAS  Google Scholar 

  100. Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG. Effect of dopamine vs. norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest. 1989;95:1282-1288.

    Article  PubMed  CAS  Google Scholar 

  101. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin E1, and sodium nitroprusside. J Heart Lung Transplant. 1995;14:436-443.

    PubMed  CAS  Google Scholar 

  102. Solina AR, Ginsberg SH, Papp D. Dose response to nitric oxide in adult cardiac surgery. J Clin Anesth. 2000;13:281-286.

    Article  Google Scholar 

  103. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 2003;99:1415-1432.

    Article  PubMed  Google Scholar 

  104. Samama CM, Diaby M, Fellahi JL, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology. 1995;83:56-65.

    Article  PubMed  CAS  Google Scholar 

  105. Yurtseven N, Karaca P, Uysal G, et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg. 2006;12: 319-323.

    Article  CAS  Google Scholar 

  106. Ziegler JW, Ivy DD, Fox JJ. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilatation in the ovine fetus. Am J Physiol. 1995;269:473-479.

    Google Scholar 

  107. Fullerton DA, Jaggers J, Piedalue F, et al. Effective control of refractory pulmonary hypertension after cardiac operations. J Thorac Cardiovasc Surg 1997;113:363–368, 368–370

    Google Scholar 

  108. Siobal M. Aerosolized prostacyclins. Respir Care. 2004;6:640-652.

    Google Scholar 

  109. Olscheweski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;9:820-824.

    Google Scholar 

  110. Hoeper MM, Olschewski H, Ghofrani HA, et al.; German PPH Study Group. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 2000;35:176-182.

    Article  Google Scholar 

  111. Stoberska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001;38:923-931.

    Article  Google Scholar 

  112. Mentzer RM, Alegre CA, Nolan SP. The effects of dopamine and isoproterenol on the pulmonary circulation. J Thorac Cardiovasc Surg. 1976;71:807-814.

    PubMed  CAS  Google Scholar 

  113. Camara ML, Aris A, Alvarez J. Hemodynamic effects of prostaglandin E1 and isoproterenol early after cardiac operations for mitral stenosis. J Thorac Cardiovasc Surg. 1992;103:1177-1185.

    PubMed  CAS  Google Scholar 

  114. Bigatello L, Hess D, Dennehy K, et al. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology. 2000;92:1827-1829.

    Article  PubMed  CAS  Google Scholar 

  115. Kerbaul F, Rondelet B, Demester JP. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2006;34:2814-2819.

    Article  PubMed  CAS  Google Scholar 

  116. Fullerton DA, Jones SD, Grover FL, et al. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg. 1996;61:1118-1124.

    Article  PubMed  CAS  Google Scholar 

  117. Auler JO, Carmona MJ, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant. 1996;15:443-450.

    Google Scholar 

  118. Rettig GF, Schieffer HJ. Acute effects of intravenous milrinone in heart failure. Eur Heart J. 1989;10:39-43.

    Article  PubMed  Google Scholar 

  119. Colucci WS. Cardiovascular effects of milrinone. Am Heart J. 1991;121:1945-1947.

    Article  PubMed  CAS  Google Scholar 

  120. Kihara S, Kawai A, Fukuda T, et al. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels. 2002;16:69-71.

    Article  PubMed  Google Scholar 

  121. Fonger JD, Borkon AM, Baumgartner WA, et al. Acute right ventricular failure following heart transplantation: Improvement with prostaglandin E1 and right ventricular assist. J Heart Transplant. 1986;5:317-321.

    PubMed  CAS  Google Scholar 

  122. Weiss CI, Park JV, Bolman RM. Prostaglandin E1 for treatment of elevated pulmonary vascular resistance in patients undergoing cardiac transplantation. Transplant Proc. 1989;21:2555-2556.

    PubMed  CAS  Google Scholar 

  123. Tritapepe L, Voci P, Cogliati A, et al. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med. 1999;27:2180-2183.

    Article  PubMed  CAS  Google Scholar 

  124. Ozdogan ME, Erer D, Iriz E, et al. Right-to-left shunt through a patent foramen ovale left open in the management of acute right heart failure after heart transplantation. J Heart Lung Transplant. 2008;27:135.

    Article  PubMed  Google Scholar 

  125. Safdar Z. Phase 2 and 3 clinical trials in pulmonary arterial hypertension. Adv Pulm Hypertens. 2008;7(1):228-234.

    Google Scholar 

  126. NIH Clinical Trials. http://clinicaltrials.gov/ct2/results?term=pulmonary+hypertension. Accessed online 01 Apr 2009

  127. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med. 2007;28:117-125.

    Article  PubMed  Google Scholar 

  128. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilatation induced by aerosolized zaprinast. Anesthesiology. 1998;88:410-416.

    Article  PubMed  CAS  Google Scholar 

  129. Salzberg SP, Filsoufi F, Anyanwu A, et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg. 2005;80: 502-506.

    Article  PubMed  Google Scholar 

  130. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005; 10:1691-1699.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Penn Presbyterian Medical Center, Philadelphia, PA, USA

    Julie John

Authors
  1. Julie John
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harold Palevsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie John .

Editor information

Editors and Affiliations

  1. Federal University of Sao Paulo, Sao Paulo, 04023900, Brazil

    Edmo Atique Gabriel

  2. University of Miami, 1611 N.W. 12th Avenue, Miami, 33136, Florida, USA

    Tomas Salerno

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer London

About this chapter

Cite this chapter

John, J., Palevsky, H. (2010). Pulmonary Arterial Hypertension. In: Gabriel, E., Salerno, T. (eds) Principles of Pulmonary Protection in Heart Surgery. Springer, London. https://doi.org/10.1007/978-1-84996-308-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-84996-308-4_21

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-307-7

  • Online ISBN: 978-1-84996-308-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation